The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System
This study highlights increasing GLP-1 RA use in pregnant women and identifies potential pregnant ADRs. GLP-1 RAs are not recommended for use during pregnancy. In cases of unintentional exposure, close monitoring is advised to ensure maternal and foetal safety. These findings provide valuable insights for clinicians making informed decisions and regulators considering using GLP-1 RA in pregnancy.
Authors
- Xuemei Wu (ORCID: https://orcid.org/0000-0003-1640-7385)
- Maobai Liu (ORCID: https://orcid.org/0000-0002-8382-7868)
- Zipeng Wei (ORCID: https://orcid.org/0000-0002-9847-337X)
- Jianxing Zhou (ORCID: https://orcid.org/0000-0003-4405-0440)
- Weipeng Lai
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1111/bcp.16354
- Citations
- 10
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 3.51